Brief: Carsgen Therapeutics Says U.S. Unit Passed Inspections Of Its Current Good Manufacturing Practice Facility
21/02/2022 01:34
Feb 21 (Reuters) - CARsgen Therapeutics Holdings Ltd
2171.HK :
* U.S. UNIT PASSED OFFICIAL INSPECTIONS OF ITS CURRENT GOOD
MANUFACTURING PRACTICE MANUFACTURING FACILITY IN NORTH CAROLINA
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer